6.16
price down icon1.28%   -0.08
 
loading
Schlusskurs vom Vortag:
$6.24
Offen:
$6.21
24-Stunden-Volumen:
990.09K
Relative Volume:
0.56
Marktkapitalisierung:
$397.75M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-3.2593
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
-8.61%
1M Leistung:
-10.85%
6M Leistung:
+183.87%
1J Leistung:
+183.87%
1-Tages-Spanne:
Value
$5.93
$6.21
1-Wochen-Bereich:
Value
$5.93
$6.8055
52-Wochen-Spanne:
Value
$1.10
$10.08

Immuneering Corp Stock (IMRX) Company Profile

Name
Firmenname
Immuneering Corp
Name
Telefon
617-500-8080
Name
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Name
Mitarbeiter
54
Name
Twitter
Name
Nächster Verdiensttermin
2025-08-08
Name
Neueste SEC-Einreichungen
Name
IMRX's Discussions on Twitter

Vergleichen Sie IMRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMRX
Immuneering Corp
6.16 402.92M 317.00K -53.47M -49.31M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.64 110.88B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
726.21 72.79B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
890.11 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
404.46 54.85B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
189.85 41.41B 447.02M -1.18B -906.14M -6.1812

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-31 Eingeleitet Leerink Partners Outperform
2024-12-13 Herabstufung Morgan Stanley Equal-Weight → Underweight
2024-03-15 Herabstufung Jefferies Buy → Hold
2024-03-15 Bestätigt Needham Buy
2024-03-15 Herabstufung TD Cowen Outperform → Market Perform
2023-12-01 Eingeleitet Needham Buy
2023-06-26 Fortgesetzt Oppenheimer Outperform
2023-04-19 Hochstufung Mizuho Neutral → Buy
2023-04-19 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-03-30 Eingeleitet Mizuho Neutral
2023-02-03 Herabstufung Morgan Stanley Equal-Weight → Underweight
2022-07-08 Eingeleitet Chardan Capital Markets Buy
2022-04-01 Eingeleitet Oppenheimer Outperform
2022-01-07 Eingeleitet Piper Sandler Overweight
Alle ansehen

Immuneering Corp Aktie (IMRX) Neueste Nachrichten

pulisher
Dec 10, 2025

Top investors say Immuneering Corp (IMRX) ticks everything they need - Setenews

Dec 10, 2025
pulisher
Dec 02, 2025

This trade activity should not be overlooked: Immuneering Corp (IMRX) - Setenews

Dec 02, 2025
pulisher
Dec 01, 2025

Immuneering (IMRX) Stock Analysis Report | Financials & Insights - Benzinga

Dec 01, 2025
pulisher
Nov 27, 2025

We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth - Yahoo Finance

Nov 27, 2025
pulisher
Nov 26, 2025

Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Nov 26, 2025
pulisher
Nov 26, 2025

Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? - Yahoo Finance

Nov 26, 2025
pulisher
Nov 25, 2025

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times

Nov 25, 2025
pulisher
Nov 24, 2025

Immuneering Corporation (IMRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 24, 2025
pulisher
Nov 24, 2025

A new trading data show Immuneering Corp (IMRX) is showing positive returns. - Setenews

Nov 24, 2025
pulisher
Nov 22, 2025

Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - Sahm

Nov 22, 2025
pulisher
Nov 20, 2025

Combining machine learning predictions for Immuneering Corporation2025 Technical Overview & Technical Pattern Based Signals - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Best data tools to analyze Immuneering Corporation stockTrend Reversal & Stepwise Trade Execution Plans - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

How Immuneering Corporation stock compares to growth peersLong Setup & Reliable Breakout Stock Forecasts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is Immuneering Corporation stock poised for growthBear Alert & Community Trade Idea Sharing - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Does Immuneering Corporation qualify in momentum factor screeningMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Can Immuneering Corporation stock reach $100 price targetEntry Point & Long-Term Safe Investment Plans - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

Will Immuneering Corporation stock beat EPS estimatesPortfolio Gains Report & High Win Rate Trade Alerts - newser.com

Nov 18, 2025
pulisher
Nov 18, 2025

Can machine learning forecast Immuneering Corporation recoveryMarket Volume Report & Entry Point Confirmation Signals - newser.com

Nov 18, 2025
pulisher
Nov 16, 2025

Is Immuneering Corporation stock undervalued vs historical averages2025 Valuation Update & Real-Time Stock Movement Alerts - newser.com

Nov 16, 2025
pulisher
Nov 15, 2025

What data driven models say about Immuneering Corporation’s futureMarket Activity Summary & Safe Entry Point Alerts - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

Why Immuneering Corporation stock is recommended by analystsWeekly Market Outlook & Fast Exit and Entry Trade Guides - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

Can momentum traders help lift Immuneering CorporationJuly 2025 Analyst Calls & Advanced Technical Analysis Signals - newser.com

Nov 15, 2025
pulisher
Nov 14, 2025

Immuneering Corporation (NASDAQ:IMRX) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 14, 2025
pulisher
Nov 13, 2025

Immuneering Corp. Shines in Positive Earnings Call - TipRanks

Nov 13, 2025
pulisher
Nov 13, 2025

What momentum indicators show for Immuneering Corporation stockWeekly Stock Report & High Return Trade Guides - newser.com

Nov 13, 2025
pulisher
Nov 13, 2025

Immuneering rises after smaller-than-expected Q3 loss - TradingView

Nov 13, 2025
pulisher
Nov 13, 2025

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates - The Manila Times

Nov 13, 2025
pulisher
Nov 12, 2025

Immuneering Corp. Reports Strong Q3 2025 Progress - TipRanks

Nov 12, 2025
pulisher
Nov 12, 2025

Earnings call transcript: Immuneering Q3 2025 emphasizes cash boost and trial progress - Investing.com Nigeria

Nov 12, 2025

Finanzdaten der Immuneering Corp-Aktie (IMRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.26
price up icon 0.45%
$95.17
price up icon 0.01%
$31.24
price up icon 1.00%
$95.73
price down icon 0.12%
biotechnology ONC
$322.68
price up icon 1.25%
$189.85
price down icon 2.22%
Kapitalisierung:     |  Volumen (24h):